How time-restricted eating changes with age
Time-restricted eating (TRE) is an eating-pattern intervention in which daily caloric intake is confined to a defined window. This page summarises registered and published research on how TRE protocols, populations and o
What time-restricted eating is
Time-restricted eating (TRE) is the formal term for an eating-pattern intervention in which all daily caloric intake is confined to a defined window, producing a corresponding fasting interval. Synonyms in the research literature include time-restricted feeding (used more often in animal work) and chrono-nutrition or ChronoFeeding when the intervention is framed around circadian alignment [7]. TRE is a behavioural schedule rather than a compound: it has no sequence, formula or molecular weight, and the evidence base consists of feeding trials and registered clinical protocols rather than pharmacological characterisation.
The mechanistic work in this area centres on circadian regulation of metabolism and on the insulin/GLP-1 receptor signalling axis, which is why TRE is frequently compared against, or combined with, GLP-1 receptor agonists such as semaglutide and tirzepatide [3].
Research Studies
TRE and appetite hormones in adults with obesity and prediabetes
The Time-Restricted Intake of Meals (TRIM) study was a 12-week randomised isocaloric and eucaloric feeding trial comparing a 10-hour TRE window against a 16-hour usual eating pattern (UEP) in adults with obesity and either prediabetes or diet-controlled type 2 diabetes. A post hoc analysis examined eating behaviour, appetite hormones and inflammatory markers, with participants completing the Three-Factor Eating Questionnaire (Restraint, Disinhibition, Hunger) and providing fasting blood samples for leptin, adiponectin, CRP, cortisol and sRAGE at pre- and post-intervention timepoints [1].
TRE and weight-loss maintenance in adults after short-term reduction
A multi-centre, two-arm randomised controlled trial across six regions in China is recruiting overweight or obese adults who have recently achieved a short-term weight reduction of at least 5% of body weight. The trial evaluates whether a 10-hour daily TRE regimen prevents weight regain more effectively than standard weight maintenance counselling alone; both arms receive the same frequency and intensity of nutritional counselling, with the eating window as the only difference [2].
TRE and cardiometabolic health during androgen deprivation therapy
The phase II IMPACT-ADT trial compares TRE and GLP-1 receptor agonists (semaglutide and tirzepatide) against an American Heart Association heart-healthy diet intervention in prostate cancer patients undergoing androgen deprivation therapy (ADT). The rationale is that ADT-related metabolic changes — increased weight, body fat and insulin resistance — raise cardiovascular risk in this population [3].
TRE combined with Urolithin A in adults with obesity
A registered study tests whether daily Urolithin A (500 mg) for 6 months supports weight loss while preserving functional muscle mass and improving markers of mitochondrial health, inflammation and metabolism in adults with obesity. All participants receive the same structured lifestyle programme covering nutrition and sleep guidance; half receive Urolithin A and half a matching placebo. The background cites aging and obesity as both linked to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress and low-grade inflammation [4].
TRE in adult survivors of childhood cancer
A study in adult survivors of childhood cancer examines whether motivational sessions, including regular calls with a trained health coach, combined with TRE achieve weight loss and lower cardiometabolic risk compared with the usual approach of reviewing educational materials and measuring weight once a month. The study does not provide treatment for any disease or cancer [5].
TRE over one year in type 2 diabetes
A one-year trial investigates the effectiveness of a TRE-based intervention on glycaemic control, body weight and composition, cardiometabolic risk factors and behaviour in individuals with overweight or obesity and type 2 diabetes [6].
TRE and chrono-nutrition in adults with ADHD
A randomised controlled pilot study of 60 adults with ADHD aged 18 to 65, who report extended eating habits of more than 14 hours a day and sleep problems, examines whether a TRE-based intervention (ChronoFeeding) improves quality of life, behaviour, sleep and gut health. Biological markers including gut and saliva microbiota, inflammation and oxidative stress are assessed in both humans and animal models [7].
TRE in polycystic ovarian syndrome
Polycystic ovarian syndrome (PCOS) is associated with metabolic symptoms including hyperinsulinaemia. A randomised controlled crossover trial tests the feasibility of an 18:6 eating protocol in PCOS management, determining whether it reduces insulin levels [8].
Comparison of registered TRE protocols by population
| Population | Protocol | Comparator | Primary focus |
|---|---|---|---|
| Adults with obesity and prediabetes or diet-controlled T2D | 10-h TRE | 16-h usual eating pattern | Appetite hormones, eating behaviour, inflammatory markers [1] |
| Overweight/obese adults after ≥5% weight loss | 10-h TRE | Standard maintenance counselling | Weight regain prevention [2] |
| Prostate cancer patients on ADT | TRE | GLP-1 RA; AHA heart-healthy diet | Cardiovascular and metabolic outcomes [3] |
| Adults with obesity | TRE plus Urolithin A 500 mg | Placebo plus same lifestyle programme | Muscle mass, mitochondrial and inflammatory markers [4] |
| Adult survivors of childhood cancer | TRE plus health coaching | Educational materials and monthly weighing | Weight loss, cardiometabolic risk [5] |
| Overweight/obese adults with T2D | TRE-based intervention, 1 year | Not specified in registry entry | Glycaemic control, body composition, behaviour [6] |
| Adults with ADHD and extended eating windows | ChronoFeeding (TRE-based) | Randomised controlled pilot | Quality of life, behaviour, sleep, gut health [7] |
| PCOS | 18:6 TRE | Crossover control | Serum insulin, insulin resistance [8] |
If you are reading this for personal health reasons
The materials and interventions described on this page are discussed in the context of laboratory and clinical research, and we do not provide dosing or medical guidance. Nothing here is a recommendation for self-administration or for altering your own eating schedule. Anyone considering a compound or an eating-pattern intervention for themselves should speak to a licensed clinician.
Sources
- [1] Time-Restricted Eating on Appetite and Inflammation in Adults With Obesity and Prediabetes: A Randomized Feeding Study
- [2] Time-Restricted Eating for Weight-Loss Maintenance
- [3] Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
- [4] Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating
- [5] A Study of Time-Restricted Eating in Childhood Cancer Survivors
- [6] Restricted Eating Time in the Treatment of Type 2 Diabetes
- [7] Developing Microbiome and Dietary Strategies Based on Chrono-nutrition for Targeting ADHD
- [8] Time-restricted Eating to Improve Metabolic Abnormalities in Polycystic Ovarian Syndrome